See more : GIB Capital Group, Inc. (GIBX) Income Statement Analysis – Financial Results
Complete financial analysis of ERYTECH Pharma S.A. (ERYP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ERYTECH Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Alpha Growth plc (ALGW.L) Income Statement Analysis – Financial Results
- Monogram Orthopaedics, Inc. (MGRM) Income Statement Analysis – Financial Results
- Sakai Chemical Industry Co., Ltd. (4078.T) Income Statement Analysis – Financial Results
- Tidal Trust II – Defiance S&P 500 Enhanced Options & 0DTE Income ETF (WDTE) Income Statement Analysis – Financial Results
- GMB Korea Corp. (013870.KS) Income Statement Analysis – Financial Results
ERYTECH Pharma S.A. (ERYP)
About ERYTECH Pharma S.A.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.36M | 4.14M | 3.36M | 19.72M | 10.78M | 6.61M | 1.80M | 3.46M |
| Cost of Revenue | 0.00 | 0.00 | 57.58M | 52.19M | 33.47M | 25.46M | 19.72M | 10.78M | 6.61M | 5.33M | 3.46M |
| Gross Profit | 0.00 | 0.00 | -57.58M | -48.83M | -29.33M | -22.10M | 0.00 | 0.00 | 0.00 | -3.53M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -1,451.52% | -708.80% | -656.90% | 0.00% | 0.00% | 0.00% | -195.63% | 0.00% |
| Research & Development | 19.91M | 45.10M | 57.58M | 52.19M | -19.72M | -25.46M | 0.00 | 0.00 | 0.00 | 2.50M | 0.00 |
| General & Administrative | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Other Expenses | -6.65M | -3.69M | -3.72M | -5.28M | -4.45M | -3.10M | -3.99M | -2.81M | -2.03M | -4.29M | -5.68M |
| Operating Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 10.15M | 5.43M | 2.67M | 4.81M | 2.34M | 1.76M | -2.39M |
| Cost & Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 43.62M | 30.89M | 22.39M | 15.58M | 8.95M | 7.09M | 1.07M |
| Interest Income | 4.45M | 13.00K | 889.00K | 2.95M | 163.00K | 405.00K | 545.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.36M | 2.14M | 5.35M | 1.53M | 9.00K | 15.00K | 4.00K | 5.00K | 6.80K | 4.66K | 9.38K |
| Depreciation & Amortization | -19.90M | 9.06M | 889.00K | 2.95M | 797.00K | 532.00K | 425.00K | 288.00K | 276.52K | 180.30K | 292.09K |
| EBITDA | -22.69M | -47.46M | -67.94M | 5.28M | 4.45M | 3.36M | -21.47M | -14.72M | -8.60M | -8.00M | -1.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,817.09% | -904.20% | -980.56% | -108.90% | -136.63% | -130.00% | -443.87% | -53.83% |
| Operating Income | -2.80M | -56.52M | -68.83M | -64.07M | -43.62M | -30.89M | -22.39M | -15.58M | -8.95M | -7.09M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,904.70% | -1,054.16% | -918.22% | -113.55% | -144.61% | -135.32% | -393.13% | -31.04% |
| Total Other Income/Expenses | 3.09M | 2.72M | -4.47M | -67.94M | -42.67M | -2.64M | 488.00K | 567.00K | 68.17K | -1.10M | -1.09M |
| Income Before Tax | 293.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.90M | -15.02M | -8.88M | -8.18M | -2.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,862.66% | -923.68% | -996.82% | -111.07% | -139.35% | -134.29% | -454.14% | -62.54% |
| Income Tax Expense | 521.00K | 2.00K | 3.00K | -1.00K | 2.00K | -3.00K | 10.00K | -3.00K | -20.16K | -40.02K | 7.64K |
| Net Income | -228.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.91M | -15.01M | -8.86M | -8.14M | -2.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,862.63% | -923.73% | -996.73% | -111.13% | -139.32% | -133.98% | -451.92% | -62.77% |
| EPS | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| EPS Diluted | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| Weighted Avg Shares Out | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
| Weighted Avg Shares Out (Dil) | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
Erytech Pharma SA (NASDAQ:ERYP ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael...
Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
Erytech Pharma (NASDAQ: ERYP ) stock is on the rise Tuesday after the company provided investors with a business update for Q1! First up is the company's planned merger with Pherecydes.
ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Gil Beyen - CEO Eric Soyer - CFO and COO Conference Call Participants Boris Peaker - Cowen Operator Good morning, and thank...
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Gil Beyen – Chief Executive Officer Eric Soyer – Chief Financial and Chief Operating Officer Dr. Iman El-Hariry – Chief Medical Officer...
Best Penny Stocks to Buy as April Ends? 3 to Watch Today
Here's what you need to know about trading penny stocks on April 25th The post Best Penny Stocks to Buy as April Ends? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Erytech Pharma Are Shares Moving Higher Today
Erytech Pharma SA (NASDAQ: ERYP) has sold its US manufacturing facility to Catalent Inc (NYSE: CTLT) for $44.5 million. Catalent will acquire Erytech's commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, with 40 people.
Why Erytech Pharma Shares Are Rising Today
Erytech Pharma SA (NASDAQ: ERYP) says that the results from the NOPHO sponsored Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients are published in the British Journal of Haematology. The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological.
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2021 Results - Earnings Call Transcript
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports